Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAC vs FA in HR+/HER2- Metastatic Breast Cancer
NCT03939897Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2020
- Primary completion
- Jun 2023
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of copanlisib in breast cancer (4 arms), sponsored by National Cancer Institute. Primary endpoint: Dose-limiting Toxicity at 28 days. Started Jun 2020; status: active, not recruiting.
02
Drugs
copanlisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03939897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03939897.